Generic Industry Likely To See Increasing Geographic Diversification – Barr
Executive Summary
The generic drug industry has myriad reasons to expand into non-U.S. markets and will continue to do so, according to Barr CEO Bruce Downey
You may also be interested in...
Barr Seeks To Capitalize On Pliva Infrastructure, Faces Obstacles To Benefits
Barr is moving ahead with its integration of Pliva, but the firm must overcome several obstacles before it can capitalize on its recently acquired European infrastructure
Barr Seeks To Capitalize On Pliva Infrastructure, Faces Obstacles To Benefits
Barr is moving ahead with its integration of Pliva, but the firm must overcome several obstacles before it can capitalize on its recently acquired European infrastructure
Generic Firms Sanguine About New Congress, Preparing For Biogeneric Action
Among a number of potential congressional actions that could benefit the generic industry, generic manufacturers appear to be most bullish about the prospects for the establishment of a pathway for follow-on biologics